India Remains Key Provider of Affordable Generics for Global Healthcare

India has played a significant role in supplying cost-effective generic drugs, supporting healthcare systems worldwide for a considerable amount of time. Yet, worries have arisen about the provision of healthcare in countries relying on these agreements due to a decrease in licensed patented drug deals. The index, which assesses 20 top pharmaceutical firms, shows a decline in non-exclusive voluntary licensing agreements crucial for generic manufacturing of vital drugs.

A decrease in voluntary licensing agreements among pharmaceutical companies may limit access to affordable medications in lower-income countries, despite the option for other manufacturers to produce patented drugs at reduced costs. Likewise, the sharing of knowledge necessary for producing local medicine mainly occurs in more affluent nations, resulting in critical shortages of medicine in regions such as sub-Saharan Africa.

In spite of these obstacles, India continues to play a crucial role in worldwide manufacturing endeavors. Out of the 20 pharmaceutical companies evaluated, five have established manufacturing plants in the country, cutting expenses and enhancing distribution networks. Furthermore, India has been involved in 11 out of the 47 worldwide technology transfer initiatives, which encompass full-scale production capacities.

Partnerships between Indian and international pharmaceutical companies highlight the opportunity to tackle urgent healthcare requirements. A collaboration has been established between Takeda and Biological E. Limited to manufacture the dengue vaccine QDENGA® (TAK-003), with the goal of reducing India’s considerable dengue impact.